Trial Watch

• Verfasst von: Cabo, Mariona [VerfasserIn]
• Verfasst von: Offringa, Rienk [VerfasserIn]
• Titel: Trial Watch
• Titelzusatz: Immunostimulatory monoclonal antibodies for oncological indications
• Verf.angabe: Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi
• Fussnoten: Gesehen am 05.04.2018
• Titel Quelle: Enthalten in: OncoImmunology
• Jahr Quelle: 2017
• Band/Heft Quelle: 6(2017,12) Artikel-Nummer e1371896, 16 Seiten
• ISSN Quelle: 2162-402X
• DOI: doi:10.1080/2162402X.2017.1371896
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1571716637

Abstract

The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.